NCT00000760View on ClinicalTrials.gov

A Randomized Study of Activity, Safety, and Tolerance of Oral Ro 24-7429 (Tat Antagonist) in Patients With HIV Infection

PHASE1CompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

Not specified

Conditions
HIV Infections
Interventions
DRUG

Ro 24-7429

DRUG

Zidovudine

DRUG

Didanosine

Trial Locations (4)

21205

Johns Hopkins Hosp, Baltimore

44106

Case Western Reserve Univ, Cleveland

92103

UCSD, San Diego

02114

Harvard (Massachusetts Gen Hosp), Boston

All Listed Sponsors
collaborator

Hoffmann-La Roche

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH